Stephen Mon Wei Chang,
PhD., Scientific Advisor

smchang55@gmail.com
(619) 743-3806

Stephen Mon Wei Chang, PhD., completed serving as the Chairman and Acting CEO of Histogen in Jan 2019 and since then has focused on three scientific disciplines: cell and gene therapy, drug delivery and research tools development. He is currently a principal and Sr VP in Kodikaz a new cell specific non-viral gene delivery platform, as well as scientific advisor to Sana, Rumi and Vita - all cell therapy platforms. Also involved as both a board member and acting CSO/CEO in Orpheus Therapeutics (cancer) and Diodem Therapeutics (dementia and obesity). Both Orpheus and Diodem use novel drug delivery platforms to treat unmet medical disease. He serves as an advisor to Mirimus, building, branding and expanding research tools in RNAi to model animal systems such as the rat and guinea pig, which has resulted in a Phase II SBIR. This has led to a novel platform that will allow rapid editing and transgenesis in many animal systems. His educational work in Connecticut and N.Y., and other ABCT programs such as Tissue Regeneration Sciences has led to his current involvement as Chief Strategist for TRS and Chief Operating Officer for TRS’s Phase II SBIR project.

Human geneticist with 32 plus years of commercial experience in life sciences in areas of stem cells, cell and gene therapy and drug development and life science tools development and sales. Entrepreneur, teacher and scientific and business leader in life science with specific emphasis on small company startups and nonprofits. Stephen Mon Wei Chang, PhD., provides leadership, strategy, startup counseling and drug development of complex drug products and organizational structure with extensive contacts. A strong believer in teams and their functions. A recognized pioneer in commercial gene therapy and complex biologicals and life science tools. Excellent speaker and media trained. Serves or has served on several government sponsored study sections. Two recent positive drug success in Instilligen rAd-fin/ syn3 (In PDUFA review) for bladder cancer and Intravail diazepam ( approved) for epilepsy are from his lab or direct involvement.

Stephen Mon Wei Chang, PhD., holds a bachelor’s degree in Zoology, Microbiology, and Cell and Molecular Biology from the University of Michigan, USPHS Postdoctoral Fellow: NIH Fellowship, Howard Hughes Medical Institute for Molecular Genetics from Baylor College of Medicine laboratory of C. Thomas Caskey, M.D and holds a Ph.D., in Biological Chemistry, Molecular Biology and Biochemistry from the University of California, Irvine.